Results 41 to 50 of about 17,271 (194)

Qiling decoction enhances the anti-tumor activity of abiraterone acetate by up-regulating miR-143 expression in abiraterone acetate-resistant prostate cancer cells

open access: yesFrontiers in Medicine
IntroductionAbiraterone acetate is a key therapeutic agent for castration-resistant prostate cancer (CRPC), but the cancer resistance limits its long-term efficacy.
Lizhi Chen   +5 more
doaj   +1 more source

A phase 3, double-blind, randomized placebo-controlled efficacy and safety study of abiraterone acetate in chemotherapy-naïve patients with mCRPC in China, Malaysia, Thailand and Russia

open access: yesAsian Journal of Urology, 2017
Objective: This double-blind, placebo-controlled phase 3 study was designed to compare efficacy and safety of abiraterone acetate + prednisone (abiraterone) to prednisone alone in chemotherapy-naïve, asymptomatic or mildly symptomatic metastatic ...
Dingwei Ye   +16 more
doaj   +1 more source

Dual Compartmentalization of GSTA4 Suppresses Ferroptosis to Drive Antiandrogen Resistance in Prostate Cancer

open access: yesAdvanced Science, EarlyView.
The schematic diagram depicts a compartmentalized anti‐ferroptotic defense mechanism mediated by GSTA4. GSTA4 is upregulated and localizes to the cytoplasm in ENZR cells, where it detoxifies 4‐HNE via a non‐canonical GSH‐dependent pathway. Under oxidative stress, GSTA4 translocates to mitochondria, interacts with PGAM5, and blocks Drp1 Ser637 ...
Yong Luo   +17 more
wiley   +1 more source

Steroid sidestep: evading androgen ablation by abiraterone

open access: yes, 2015
Tumor mechanisms of abiraterone resistance in clinical prostate cancer are not well defined. Chen and colleagues report that a T878A androgen receptor mutation occurs in a subset of patients progressing while receiving abiraterone, suggesting that this ...
Sharifi, Nima
core   +1 more source

Inhibition of AKR1C3 Activation Overcomes Resistance to Abiraterone in Advanced Prostate Cancer [PDF]

open access: yes, 2017
Abiraterone suppresses intracrine androgen synthesis via inhibition of CYP17A1. However, clinical evidence suggests that androgen synthesis is not fully inhibited by abiraterone and the sustained androgen production may lead to disease relapse.
Lombard, Alan   +5 more
core   +1 more source

AKT1 regulates UHRF1 protein stability and promotes the resistance to abiraterone in prostate cancer

open access: yesOncogenesis, 2023
Oncogenic activation of PI3K/AKT signaling pathway, together with epigenetic aberrations are the characters of castration-resistant prostate cancer (CRPC).
Yongming Fu   +8 more
doaj   +1 more source

Drug Repurposing for Treating NCOR‐Related Intellectual Disability

open access: yesAdvanced Science, EarlyView.
An autism‐associated NCOR1 heterozygous mutation upregulates NRGs and activates NRG backward signaling in hypothalamic GABAergic neurons in mouse models, leading to Gabra2 downregulation and cognitive deficits, which can be therapeutically targeted by repurposing FDA‐approved drugs.
Yan Kong   +15 more
wiley   +1 more source

Idarubicin combats abiraterone and enzalutamide resistance in prostate cells via targeting XPA protein

open access: yesCell Death and Disease, 2022
Although second-generation therapies like abiraterone (ABI) and enzalutamide (ENZ) benefit patients with castration-resistant prostate cancer (CRPC), drug resistance frequently occurs, eventually resulting in therapy failure.
Ying Zhang   +11 more
doaj   +1 more source

Mechanism‐Informed Language Modeling and Oxygenated 3D Screening Identify Berberine–Enzalutamide Synergy in Prostate Cancer Models

open access: yesAdvanced Science, EarlyView.
By integrating knowledge‐augmented artificial intelligence with an oxygen‐supplemented 3D screening platform, a synergistic interaction between berberine and enzalutamide is identified. The framework integrates compound mechanisms of action with disease‐relevant signaling context to prioritize candidate combinations and generate testable pathway‐based ...
Chih‐Hui Lo   +15 more
wiley   +1 more source

Localized Prostate Cancer Therapy: Tumor Microenvironment‐Activated Spermine Hydrogel With Real‐Time Autonomous Fluorescence Sensing

open access: yesChemistry – A European Journal, EarlyView.
First tumor microenvironment (TME)‐responsive spermine‐loaded hydrogel with autonomous sensing for advanced local therapy of prostate cancer (PCa) is developed. Spermine can be released from the hydrogel to kill the prostate cancer cells specifically under acidic TME.
Ho‐Fai Chau   +12 more
wiley   +1 more source

Home - About - Disclaimer - Privacy